• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

中国药物评价 ›› 2025, Vol. 42 ›› Issue (2): 116-120.

• 药品评价 • 上一篇    下一篇

心脉隆注射液联合瑞舒伐他汀对慢性心力衰竭患者心功能及血管内皮功能的影响

 赵琳1, 张燕2, 彭亮2   

  1. 1.驻马店市第一人民医院心内一病区, 河南 驻马店 463000;
    2.阜外华中心血管病医院冠心病二病区, 河南 郑州 451450
  • 收稿日期:2025-01-26 修回日期:2025-03-06 出版日期:2025-04-28 发布日期:2025-04-28

The Effect of Xinmailong Injection Combined with Rosuvastatin on Cardiac Function and Vascular Endothelial Function in Patients with Chronic Heart Failure

  1. 1.The First Ward of the Heart of Zhumadian First People′s Hospital, Henan Zhumadian 463000, China;
    2.The Second Ward of Coronary Heart Disease, Fuwai Hua Central Vascular Disease Hospital, Henan Zhengzhou 451450, China
  • Received:2025-01-26 Revised:2025-03-06 Online:2025-04-28 Published:2025-04-28

摘要: 目的:探讨慢性心力衰竭(CHF)患者应用心脉隆注射液联合瑞舒伐他汀对心功能及血管内皮功能的影响。方法:收集2022年8月至2024年9月入院的102例CHF患者资料,开展回顾性研究。根据试验匹配设计原则(1∶1)按治疗方法不同分为两组,其中对照组采用常规治疗+瑞舒伐他汀治疗,研究组在对照组基础上联合心脉隆注射液治疗。两组均持续治疗14 d。比较两组临床疗效,治疗前、治疗14 d后的中医证候积分、明尼苏达心力衰竭生活质量问卷(MLHFQ)、心功能及运动耐力[左室舒张末内径(LVEDD)、左室射血分数(LVEF)、二尖瓣血流舒张早期流速(VE)与心房收缩期流速(VA)比值(VE/VA)、6 min步行距离(6MWD)]、血管内皮功能[一氧化氮(NO)、内皮素-1(ET-1)、血管内皮生长因子(VEGF)]及不良反应发生情况。结果:研究组疗效优于对照组(P<0.05);治疗14 d后研究组的心悸、气短乏力、畏寒肢冷、唇甲青紫、MLHFQ评分均低于对照组(P<0.05);治疗14 d后两组LVEF、VE/VA、6MWD、NO均上升,LVEDD、ET-1、VEGF均下降,其中研究组改善幅度更明显(P<0.05);组间不良反应对比无显著差异(P>0.05)。结论:心脉隆注射液联合瑞舒伐他汀可提高CHF患者疗效,改善临床症状及生活质量,提升心功能及运动耐力,增强血管内皮功能。

关键词: font-size:medium, ">慢性心力衰竭;心脉隆注射液;瑞舒伐他汀;心功能;血管内皮功能

Abstract: Objective: To investigate the effect of Xinmailong injection combined with Rosuvastatin on cardiac function and vascular endothelial function in patients with chronic heart failure(CHF). Methods: Data from 102 CHF patients admitted to our hospital between August 2022 and September 2024 were collected for retrospective study. According to the experimental matching design principle(1∶1), the patients were divided into two groups based on different treatment methods. Among them, 51 cases in the control group were treated with conventional therapy+Rosuvastatin, and 51 cases in the study group were treated with Xinmailong injection in addition to the control group. Both groups were treated for 14 days. The clinical efficacy and adverse reactions of the two groups were compared, as well as the TCM syndrome scores, Minnesota Living with Heart Failure Questionnaire(MLHFQ), cardiac function and exercise tolerance [left ventricular end-diastolic diameter(LVEDD), left ventricular ejection fraction(LVEF), ratio of early diastolic flow velocity(VE) to atrial systolic flow velocity(VA) in mitral valve flow(VE/VA), 6-minute walk distance(6MWD)], vascular endothelial function [nitric oxide(NO), endothelin-1(ET-1), vascular endothelial growth factor(VEGF)] before and after treatment for 14 days. Results: The therapeutic efficacy of the study group was superior to that of the control group(P<0.05). After 14 days of treatment, the study group had lower scores in palpitations, shortness of breath, fatigue, chills, cold limbs, blue lips and nails, and MLHFQ scores than the control group(P<0.05). After 14 days of treatment, LVEF, VE/VA, 6MWD, and NO in both groups were increased, while LVEDD, ET-1, and VEGF were decreased, the improvement in the study group was more significant(P<0.05). There was no significant difference in adverse reactions between the groups(P>0.05). Conclusion: Xinmailong injection combined with Rosuvastatin can improve the efficacy of CHF patients, improve clinical symptoms and quality of life, enhance cardiac function and exercise tolerance, and enhance vascular endothelial function.

Key words: font-size:medium, ">Chronic heart failure; Xinmailong injection; Rosuvastatin; Heart function; Vascular endothelial function

中图分类号: